AIM WINNERS & LOSERS: Tiger Royalties to buy Bixby Technologies
20th Dec 2024 10:52
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Synairgen PLC - South Hampton, England-based drug discovery and development company focused on combatting respiratory disease - In 2023, pretax loss narrowed to GBP9.7 million from GBP20.1 million a year prior. No revenue generated. Research & Development expenditure down 56% to GBP6.5 million from GBP14.9 million. Other administrative expenses fell 30% to GBP3.8 million from GBP5.4 million. Cash and cash equivalents held at GBP10.5 million, down 34% from GBP15,9 million. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday: Read More
Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Appoints Joseph Colliver as chief financial officer with effect from November 6. Current CFO John Ward will step down from his role on November 3. Colliver has previously held CFO and senior commercial roles at Sativa Group Inc, and within the Kantar division of WPP PLC. He is currently CFO at Phytome Life Sciences Ltd, a pharmaceutical manufacturing firm focused on plant-based medicines. Read More
(Alliance News) - Synairgen PLC on Tuesday promoted Marcin Mankowski to chief medical officer, effective immediately. Read More
Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Pretax loss narrows to GBP5.2 million in six months that ended June 30 from GBP14.0 million a year before. Has no revenue either year, but research and development spending is reduced to GBP3.5 million from GBP11.1 million, as phase 3 Sprinter trial of SNG001 is mostly completed in 2022. Since the start of the second half, receives GBP2.4 million R&D tax credit, which adds to GBP14.6 million cash balance on June 30. Read More
(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Synairgen PLC on Tuesday said it had received positive data from its ACTIV-2 Phase 2 trial for its antiviral treatment. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Posts positive from its Phase 2 clinical trial of inhaled SNG001 in virally infected chronic obstructive pulmonary disease patients. Says findings from assessments of lung sputum samples show viral clearance from the lower respiratory tract. SNG001 is a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Records a pretax loss of GBP57.9 million in 2021, widened from GBP17.7 million in 2020, as research and development costs jump to GBP52.9 million from GBP15.5 million. Further, administrative expenses more than double to GBP5.0 million from GBP2.2 million. Explains this with its phase 3 Sprinter trial that started patient recruitment in January 2021. The trial is for SNG001, an inhaled drug for the treatment of Covid-19. Says the remainder of the research and development expenditure was used for upscaling SNG001 manufacturing development activities and procuring long lead time components. Read More
(Alliance News) - The FTSE 100 index put a toe into positive territory by midday on Monday, reclaiming all the ground lost earlier in the morning, but investors continue to fret about poor economic data from China. Read More